|
1.
|
|
9 p, 627.4 KB |
Effects of alirocumab on types of myocardial infarction : Insights from the ODYSSEY OUTCOMES trial
/
White, Harvey D. (Auckland City Hospital) ;
Gabriel Steg, P. (Royal Brompton Hospital (Londres)) ;
Szarek, Michael (SUNY Downstate Medical Center School of Public Health) ;
Bhatt, Deepak L (Harvard Medical School) ;
Bittner, Vera A. (University of Alabama at Birmingham) ;
Diaz, Rafael (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Erglis, Andrejs (University of Latvia) ;
Goodman, Shaun G. (University of Toronto) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Department of Medicine) ;
Wouter Jukema, J. (Leiden University Medical Center) ;
Lopes, Renato D. (Duke Clinical Research Institute) ;
Mahaffey, Kenneth W. (Stanford University School of Medicine) ;
Moryusef, Angele (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals) ;
Roe, Matthew T. (Duke Clinical Research Institute) ;
Sritara, Piyamitr (Mahidol University) ;
Tricoci, Pierluigi (CSL Behring) ;
Zeiher, Andreas Michael (Goethe University) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Cequier Fillat, Angel R. (Hospital Universitari de Bellvitge) ;
Garcia-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. [...]
2019 -  10.1093/eurheartj/ehz299
European heart journal, Vol. 40 Núm. 33 (january 2019) , p. 2801-2809
|
|
|
2.
|
|
10 p, 396.0 KB |
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events : The ODYSSEY OUTCOMES Trial
/
Szarek, Michael (State University of New York) ;
White, Harvey D. (University of Auckland and Green Lane Cardiovascular Services Auckland City Hospital) ;
Schwartz, Gregory G. (Division of Cardiology. University of Colorado School of Medicine) ;
Alings, Marco (Amphia Ziekenhuis Molengracht) ;
Bhatt, Deepak L (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ;
Bittner, Vera A. (University of Alabama at Birmingham) ;
Chiang, Chern-En (Taipei Veterans General Hospital and National Yang-Ming University) ;
Diaz, Rafael (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Goodman, Shaun G. (University of Toronto) ;
Hanotin, Corinne (Sanofi) ;
Harrington, R.A. (Stanford University) ;
Jukema, J.Wouter (Leiden University Medical Center) ;
Kimura, Takeshi (Kyoto University Graduate School of Medicine) ;
Kiss, Robert Gabor (Magyar Honvédség Egészségügyi Központ) ;
Lecorps, Guillaume (Sanofi) ;
Mahaffey, Kenneth W. (Stanford University) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals Inc.) ;
Roe, Matthew T. (Duke University Medical Center) ;
Tricoci, Pierluigi (Duke University Medical Center) ;
Xavier, Denis (St. John's Medical College and Research Institute) ;
Zeiher, Andreas Michael (Goethe University) ;
Steg, Ph Gabriel (Royal Brompton Hospital (Londres)) ;
Cequier Fillat, Angel R. (Hospital Universitari de Bellvitge) ;
Garcia-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
The ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. [...]
2019 - 10.1016/j.jacc.2018.10.039
Journal of the American College of Cardiology, Vol. 73 Núm. 4 (may 2019) , p. 387-396
|
|
|
3.
|
|
10 p, 324.1 KB |
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome : ODYSSEY OUTCOMES Trial
/
Jukema, J.Wouter (Leiden University Medical Center) ;
Szarek, Michael (State University of New York) ;
Zijlstra, Laurien E. (Leiden University Medical Center) ;
de Silva, H.Asita (University of Kelaniya) ;
Bhatt, Deepak L (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ;
Bittner, Vera A. (University of Alabama at Birmingham) ;
Diaz, Rafael (Cardiovascular Institute of Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Goodman, Shaun G. (St. Michael's Hospital. University of Toronto) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Stanford University) ;
Karpov, Yuri (Russian Cardiological Scientific-Productive Complex) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals. Inc.) ;
Prieto, Juan C. (University of Chile Clinical Hospital) ;
Roe, Matthew T. (Duke University School of Medicine) ;
White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ;
Zeiher, Andreas Michael (Goethe University) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Steg, P.Gabriel (Royal Brompton Hospital (Londres)) ;
Cequier, Ángel (Hospital Universitari de Bellvitge) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Mata Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. [...]
2019 - 10.1016/j.jacc.2019.03.013
Journal of the American College of Cardiology, Vol. 74 Núm. 9 (march 2019) , p. 1167-1176
|
|
|
4.
|
|
12 p, 648.4 KB |
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
/
Bittner, Vera A. (University of Alabama at Birmingham) ;
Szarek, Michael (State University of New York) ;
Aylward, Philip (South Australian Health and Medical Research Institute) ;
Bhatt, Deepak L. (Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School) ;
Díaz, Rafaël J. (Instituto Cardiovascular de Rosario) ;
Edelberg, Jay M. (Sanofi) ;
Fras, Zlatko (Univerza V Ljubljani) ;
Goodman, Shaun G. (University of Toronto) ;
Halvorsen, Sigrun (University of Oslo) ;
Hanotin, Corinne (Sanofi) ;
Harrington, Robert A. (Stanford University) ;
Jukema, J. Wouter (Leiden University Medical Center) ;
Loizeau, Virginie (Sanofi) ;
Moriarty, Patrick Maurice (University of Kansas Medical Center) ;
Moryusef, Angèle (Sanofi) ;
Pordy, Robert (Regeneron Pharmaceuticals Inc.) ;
Roe, Matthew T. (Duke University School of Medicine) ;
Sinnaeve, Peter (University of Leuven) ;
Tsimikas, Sotirios (University of California San Diego) ;
Vogel, Robert A. (University of Colorado School of Medicine) ;
White, Harvey D. (Green Lane Cardiovascular Services Auckland City Hospital) ;
Zahger, Doron (Soroka University Medical Center) ;
Zeiher, Andreas Michael (Goethe University) ;
Steg, Philippe Gabriel (Royal Brompton Hospital (Londres)) ;
Schwartz, Gregory G. (University of Colorado School of Medicine) ;
Matas Pericas, Laia (Institut d'Investigació Biomèdica Sant Pau) ;
Gusi Tragant, Gabriel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Coca Payeras, Antonio (Hospital Clínic i Provincial de Barcelona) ;
Cequier, Ángel (Hospital Universitari de Bellvitge) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Bruguera Cortada, Jordi (Hospital del Mar (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). [...]
2020 - 10.1016/j.jacc.2019.10.057
Journal of the American College of Cardiology, Vol. 75 Núm. 2 (21 2020) , p. 133-144
|
|
|
5.
|
|
9 p, 925.7 KB |
The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction : the BAMI trial
/
Mathur, Anthony (Centre for Cardiovascular Medicine & Devices, Queen Mary University of London) ;
Fernández Avilés, F. (Hospital General Universitario Gregorio Marañón) ;
Bartunek, Jozef (Cardiovascular Center, OLV Hospital Aalst) ;
Belmans, Ann (KU) ;
Crea, Filippo (Fondazione Policlinico Universitario A. Gemelli IRCCS) ;
Dowlut, Sheik (Centre for Cardiovascular Medicine & Devices, Queen Mary University of London) ;
Galiñanes, Manuel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Good, Marie-Claire (Queen Mary University of London) ;
Hartikainen, Juha (Kuopio University Hospital ( Finlàndia)) ;
Hauskeller, Christine (University of Exeter) ;
Janssens, Stefan (University Hospitals Leuven (Bèlgica)) ;
Kala, Petr (University Hospital Brno (República Txeca)) ;
Kastrup, Jens (University of Copenhagen) ;
Martin, John (University College London) ;
Menasché, Philippe (Department of Cardiovascular Surgery, Hôpital Européen Georges Pompidou and University of Paris) ;
Sanz-Ruiz, Ricardo (Hospital General Universitario Gregorio Marañón) ;
Ylä-Herttuala, Seppo (University of Eastern Finland) ;
Zeiher, Andreas Michael (Department of Medicine III, Goethe University of Frankfurt) ;
Universitat Autònoma de Barcelona
Bone marrow-derived mononuclear cell (BM-MNC) therapy may improve myocardial recovery in patients following acute myocardial infarction (AMI), though existing trial results are inconsistent. Originally an open-label, multicentre Phase III trial, BAMI was designed to demonstrate the safety and efficacy of intracoronary infusion of BM-MNCs in reducing the time to all-cause mortality in patients with reduced left ventricular ejection fraction (LVEF, ≤45%) after primary angioplasty (PPCI) for ST-elevation AMI. [...]
2020 - 10.1093/eurheartj/ehaa651
European heart journal, Vol. 41 (august 2020) , p. 3702-3710
|
|
|
6.
|
|
6 p, 617.5 KB |
The effect of intracoronary infusion of bone marrow-derived mononuclear cells on all-cause mortality in acute myocardial infarction : rationale and design of the trial
/
Mathur, Anthony (Queen Mary University of London) ;
Arnold, Roman (Hospital Clínico Universitario de Valladolid) ;
Assmus, Birgit (Johann-Wolfgang-Goethe University (Germany)) ;
Bartunek, Jozef (VZW Cardiovascular Research Center Aalst (Belgium)) ;
Belmans, Ann (KU Leuven-University of Leuven & Universiteit Hasselt (Belgium)) ;
Bönig, Halvard (Johann-Wolfgang-Goethe University (Germany)) ;
Crea, Filippo (Catholic University of the Sacred Heart (Italy)) ;
Dimmeler, Stefanie (Johann-Wolfgang-Goethe University (Germany)) ;
Dowlut, Sheik (Queen Mary University of London) ;
Fernández Avilés, F. (Hospital General Universitario Gregorio Marañón) ;
Galiñanes, Manuel (Hospital Universitari Vall d'Hebron) ;
García-Dorado, David (Hospital Universitari Vall d'Hebron) ;
Hartikainen, Juha (Kuopio University Hospital ( Finlàndia)) ;
Hill, Jonathan (King's College Hospital NHS Foundation Trust) ;
Hogardt-Noll, Annette (t2cure (Germany)) ;
Homsy, Christian (Celyad SA (Belgium)) ;
Janssens, Stefan (University Hospitals Leuven (Bèlgica)) ;
Kala, Petr (Faculty Hospital and Masaryk University (Czech Republic)) ;
Kastrup, Jens (University of Copenhagen) ;
Martin, John (University College London (UK)) ;
Menasche, Philippe (University Paris Descartes. Assistance Publique Hopitaux de Paris (France)) ;
Miklik, Roman (Faculty Hospital and Masaryk University (Czech Republic)) ;
Mozid, Abdul (Barts Heart Centre (UK)) ;
San Román, J. Alberto (Hospital Clínico Universitario de Valladolid) ;
Sanz-Ruiz, Ricardo (Hospital General Universitario Gregorio Marañón) ;
Tendera, Michal (Medical University of Silesia (Poland)) ;
Wojakowski, Wojtek (Medical University of Silesia (Poland)) ;
Ylä-Herttuala, Seppo (Kuopio University Hospital ( Finlàndia)) ;
Zeiher, Andreas Michael (Johann-Wolfgang-Goethe University (Germany)) ;
Universitat Autònoma de Barcelona
Over the past 13 years bone marrow-derived mononuclear cells () have been widely investigated for clinical efficacy in patients following acute myocardial infarction (). These early phase trials have used various surrogate markers to judge efficacy and, although promising, the results have been inconsistent. [...]
2017 - 10.1002/ejhf.829
European Journal of Heart Failure, Vol. 19, Issue 11 (November 2017) , p. 1545-1550
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
